Stoke Therapeutics (NASDAQ:STOK) Shares Up 10.3% - Still a Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) rose 10.3% during trading on Tuesday . The company traded as high as $10.90 and last traded at $10.93. Approximately 899,462 shares were traded during mid-day trading, an increase of 28% from the average daily volume of 703,910 shares. The stock had previously closed at $9.91.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on STOK. HC Wainwright decreased their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and a consensus target price of $23.20.

Stoke Therapeutics Price Performance

The company has a market capitalization of $593.47 million, a P/E ratio of -5.18 and a beta of 1.20. The company has a fifty day moving average price of $8.58 and a two-hundred day moving average price of $9.67.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,748 shares of company stock worth $225,687 over the last ninety days. Insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its position in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock worth $1,028,000 after acquiring an additional 1,330 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Stoke Therapeutics by 8.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock worth $3,774,000 after purchasing an additional 25,995 shares during the period. Swiss National Bank raised its holdings in shares of Stoke Therapeutics by 20.4% in the 4th quarter. Swiss National Bank now owns 67,300 shares of the company's stock valued at $742,000 after acquiring an additional 11,400 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $113,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.